Advertisement
UK markets open in 5 hours 7 minutes
  • NIKKEI 225

    38,245.45
    +693.29 (+1.85%)
     
  • HANG SENG

    16,977.48
    +148.55 (+0.88%)
     
  • CRUDE OIL

    83.32
    -0.04 (-0.05%)
     
  • GOLD FUTURES

    2,331.80
    -10.30 (-0.44%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • Bitcoin GBP

    53,622.52
    -78.83 (-0.15%)
     
  • CMC Crypto 200

    1,435.99
    +21.23 (+1.50%)
     
  • NASDAQ Composite

    15,696.64
    +245.33 (+1.59%)
     
  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     

US STOCKS-Biotech among biggest Nasdaq gainers

* Indexes up: Dow 1 pct, S&P 0.9 pct, Nasdaq 0.9 pct

By Ryan Vlastelica

NEW YORK, Sept 26 (Reuters) - Biotech stocks were among the biggest percentage gainers on the Nasdaq on Friday, though the benchmark index only posted mild gains on the day.

Agios Pharmaceuticals (NasdaqGS: AGIO - news) surged 20 percent to $64.02 on its heaviest one-day volume since its initial public offering last year. Earlier, the company said it would present clinical data from an ongoing phase I study.

Among other big gainers, Repros Therapeutics (NasdaqCM: RPRX - news) climbed 18 percent to $10.59 after reporting the trial results for its secondary hypogonadism treatment. Esperion Therapeutics (Stuttgart: 0ET.SG - news) was up 16 percent at $20.95. Both stocks moved on volume that was much heavier than average.

ADVERTISEMENT

Despite the gains, the Nasdaq Biotech index was up a more moderate 0.3 percent. The index was pressured as AcelRx plummeted 19 percent to $5.44 after saying it was looking to resubmit the new drug application for its Zalviso product in the first quarter of 2015.

Index snapshot at 14:20 EDT:

* S&P 500 was rising 16.96 points, or 0.86 percent.

* Nasdaq Comp was gaining 40.11 points, or 0.9 percent.

* Dow industrials was adding 171.56 points, or 1.01 percent.

* Russell 2000 was adding 6.75 points, or 0.61 percent.

* S&P MidCap was adding 8.78 points, or 0.64 percent.

* S&P SmallCap was gaining 2.99 points, or 0.47 percent. (Editing by Nick Zieminski)